BioPharma Credit PLC
30 September 2026
30 September 2026
BIOPHARMA CREDIT PLC
(THE "COMPANY")
DIVIDEND DECLARATION
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the quarterly financial period ended 30 September 2026 of 1.75 cents per ordinary share, payable on 6 November 2026 to ordinary shareholders on the register as at close of business on 9 October 2026. The ex-dividend date will be 8 October 2026.
The Company aims to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from its investments in the life sciences industry. The Company currently pays, and continues to target, a 7-cent base annual dividend per ordinary share in four quarterly payments of 1.75 cents per share. Typically, these are supplemented by excess income in the form of special dividend distributions in Q4 (or, in some years, Q3 and Q4) when the Board determines that it is appropriate and possible to do so (noting the requirement to pay out substantially all income to maintain the Company's investment trust status).
Dividends in recent years:
|
Financial year (ended 31 December) |
Amount (US cents) |
|
2025 |
9.95 |
|
2024 |
10.18 |
|
2023 |
10.21 |
By way of reference, the Company's shares traded as at close of business on 29 September 2026 at a price of 98.40 cents.
The default currency for dividends is US dollars. However, shareholders can elect to have dividends paid in sterling (GBP) and the option to elect for a sterling payment for this dividend will be available to shareholders until 9 October 2026.
The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company.
A copy of the Dividend Currency Election Form, which should be sent to MUFG Corporate Markets, Central Square, 29 Wellington St, Leeds LS1 4DL when completed, will be available on the Company's website at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST.
Enquiries:
BioPharma Credit plc
via MUFG Corporate Governance Limited
Company Secretary
+44 (0) 333 300 1932
Burson Buchanan
Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill
+44 (0) 20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.